CClinicalTrials.gg
TerminatedNCT06364657IIRUpdated Jan 15, 2025

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

An observational study in Sjogren's Syndrome, Dry Eye and Neurotrophic Keratitis, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Johns Hopkins University · Observational

Why this study was terminated
The study was prematurely closed to enrollment due to the principal investigator's departure from the institution (Johns Hopkins University).
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
13
Ages
18 Years and older
Sex
All
01

Study summary

In this study the investigators plan to enroll three groups of patients: non-Sjogren's dry eye, Sjogren's dry eye and controls. The study has the following primary goals:

  1. To determine whether dry eye is associated with reduced corneal sensation
  2. To determine whether reduced corneal sensation is due to the severity of the dry eye, the type of dry eye (primarily aqueous deficient versus primarily evaporative) or entirely related to the presence of Sjogren's
  3. To determine whether corneal sensation is associated with ocular or systemic pain symptoms Additionally, the study aims to compare the novel corneal esthesiometer measurements to confocal biomicroscopy findings in determining neurotrophic keratitis (NK) and assess correlations between corneal sensation.
02

Conditions studied

  • Sjogren's Syndrome
  • Dry Eye
  • Neurotrophic Keratitis

Keywords

  • Sjogren's Syndrome
  • Dry Eye
  • Neurotrophic Keratitis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older, with and without Sjogren's-related dry eye, and no previous diagnosis of dry eye or other ocular surface disease.

Inclusion criteria

  • Male or female aged 18 or older
  • Capacity to give informed consent
  • Self-reported literacy
  • Best corrected visual acuity at distance 20/40 in each eye
  • Signed Institutional Review Board (IRB)-approved consent agreeing to the terms of the study For Sjogren's-related dry eye, the below inclusion criteria will be required

    • a previous diagnosis of dry eye made by an eye care specialist
    • a previous diagnosis of Sjogren's made according to the 2016 revised Sjogren's classification criteria

Exclusion criteria

Exclusion Criteria:

  • ● Age less than 18 years

    • Physical or mental issues, illiteracy, or language problems that might possibly interfere with reading ability or other condition that would preclude successful participation in this study
    • Contact lens wear within 10 days of enrollment
    • Any intraocular surgery (including cataract surgery) within the last 3 months
    • Any minor ocular surgery including tear duct cauterization or plugs within the last 30 days
    • Any history of corneal surgery (including LASIK/PRK) or cosmetic lid surgery in the past 12 months
    • Any history of glaucoma surgery (e.g., trabeculectomy or a tube shunt)
    • Best corrected vision worse than 20/40
    • Known history of severe ocular surface disease that might cause corneal haze and interfere with corneal staining score including but not limited to graft-versus-host disease, mucous membrane pemphigoid, atopic keratoconjunctivitis
    • Presence of keratoconus
    • Concurrent epithelial corneal disease or dystrophy (e.g., anterior basement membrane disease, pterygium, or scarring) that might affect the corneal staining score
    • Previous use of OXERVATE® for neurotrophic keratitis
    • Neurotrophic keratoconjunctivitis or corneal/conjunctival scarring (history of herpes simplex virus or varicella zoster virus keratitis)
    • Any blepharitis eyelid procedures such as Intense Pulsed Light (IPL), low level light treatment therapy, LipiFlow®, or nasolacrimal duct probing in the last 30 days prior to the study visit
    • Any acupuncture or physical therapy on the face or head within the past 3 months
    • Current smoker (within the past year)
    • Pregnant or nursing
    • Artificial tear use within 2 hours of study visit
    • Topical ophthalmic non-steroidal anti-inflammatory drug use 24 hours before the study visit
    • History of taking or current use of topical glaucoma drops or neurostimulation drugs or devices for treating dry eye
    • History or current intravitreal injections for macular degeneration
    • History of continuous positive airway pressure usage in the past 3 months
    • Any concurrent medical condition that in the judgment of the PI might interfere with the conduct of the study, confound the interpretation of the study results.
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
13 participants (actual)
Patient registry
No

Groups and cohorts

  • Sjogren's related dry-eye

    Patients over the age of 18 years with known dry eye with underlying Sjogren's syndrome. Includes a previous diagnosis of dry eye made by an eye care specialist and a previous diagnosis of Sjogren's made according to the 2016 revised Sjogren's classification criteria.

    Diagnostic Test: Eye Exam

  • non-Sjogren's related dry-eye

    Patients over the age of 18 years with known dry eye without underlying Sjogren's syndrome. Includes a previous diagnosis of dry eye made by an eye care specialist and a previous diagnosis of Sjogren's according to the 2016 revised Sjogren's classification criteria was definitively excluded

    Diagnostic Test: Eye Exam

  • Control

    Age-matched healthy controls with no known history of ocular surface diseases or dry eye or any underlying autoimmune disease

    Diagnostic Test: Eye Exam

Interventions

  • Diagnostic testEye Exam

    * Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS) * Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey * Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test. * Corneal esthesiometer for measurement of corneal sensation * Schirmer's without topical anesthesia * Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT) * Staining for dry eye: * Tear film break-up time (BUT) using fluorescein. * Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS)) * Lissamine green staining (OSS and Oxford) * Non-contact confocal biomicroscopy for morphology of the ocular surface

05

What researchers measure

Primary outcomes

  1. Corneal Epithelium health

    Measuring epithelial staining score and epithelial thickness map using anterior segment Optical coherence tomography (OCT)

    Time frame: 1 Day

  2. Corneal Nerve health

    Corneal sensation using non-contact esthesiometer and corneal nerve density and morphology using non-contact confocal biomicroscopy

    Time frame: 1 Day

Secondary outcomes

  1. Correlations Between Corneal Staining Score

    Correlations between corneal staining score with visual parameters, epithelial thickness map, corneal nerve density and morphology, and corneal sensation

    Time frame: 1 Day

  2. Correlations Between Patient Symptoms

    Correlations between the patient symptoms and above corneal findings using Ocular Surface Disease Index (OSDI), Visual Acuity Scale (VAS), and pain scale questionnaire

    Time frame: 1 Day

06

Study locations

1 site
  • Johns Hopkins Hospital Wilmer Eye Institute
    Baltimore, Maryland 21287, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06364657
Lead sponsor
Johns Hopkins University
Collaborators
Dompe U.S. Inc
Responsible party
Sponsor
First posted
Apr 15, 2024
Start date
Jul 1, 2024
Primary completion
Dec 19, 2024
Completion
Dec 19, 2024
Last update
Jan 15, 2025

Study contacts

Esen K Akpek, MD
principal investigator · Johns Hopkins Hospital Wilmer Eye Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion